American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6327)
  2. Solid Tumor Oncology Division (5470)
  3. Survivorship Research (1978)
  4. Genitourinary Oncology Service (1750)
  5. Surgery (1623)
  6. Epidemiology and Biostatistics (1466)
  7. GSK Faculty (1371)
  8. Population Sciences Research Program (1355)
  9. Gastrointestinal Oncology Service (1341)
  10. Hematologic Malignancies, Division of (1267)
Search Within
Formats
  1. Meeting Abstract (6252)
  2. Journal Article (2553)
  3. Editorial (71)
  4. Review (65)
  5. Guidelines (53)
  6. Correspondence (47)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6327)
  2. Solid Tumor Oncology Division (5470)
  3. Survivorship Research (1978)
  4. Genitourinary Oncology Service (1750)
  5. Surgery (1623)
  6. Epidemiology and Biostatistics (1466)

More Groups

People
  1. Robert Motzer (447)
  2. Howard Scher (334)
  3. Eileen O'Reilly (302)
  4. Leonard Saltz (283)
  5. Dean Bajorin (278)
  6. Mark Kris (252)

More People

Years
  1. 2025 (156)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. JCO Precision Oncology (165)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. ASCO Connection (3)

More Publications

Results (9048)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
    Meeting Abstract

    Cytryn, S. L.; Maron, S. B.; Janjigian, Y. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Preclinical and phase 1/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with EGFR or FGFR2 amplifications
    Meeting Abstract

    Maron, S. B.; Sharma, M. R.; Spira, A. I.; Rodriguez Rivera, I. I.; Chawla, S. P.; Philipovskiy, A.; Johnson, M. L.; Falchook, G. S.; Wainberg, Z. A.; Hansen, R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur)
    Meeting Abstract

    Romesser, P. B.; Miller, E. D.; Shi, Q.; Dixon, J. G.; Gholami, S.; White, S. B.; Wu, C.; Goulet, C. C.; Jee, K. W.; Wright, C. L.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors
    Meeting Abstract

    Papadopoulos, K. P.; Cecchini, M.; Khushman, M. M.; Pelster, M.; Rodon Ahnert, J.; Kummar, S.; Yaeger, R.; Sharma, S.; Wells, A. L.; Garofalo, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)
    Meeting Abstract

    Janjigian, Y. Y.; Shitara, K.; Elimova, E.; Zhang, J.; Chen, M. H.; Smyth, E. C.; Lee, J.; Miao, R.; Liu, S.; Holmblad, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Shitara, K.; Enzinger, P. C.; Mohapatra, A.; Janjigian, Y. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma
    Meeting Abstract

    Oh, D. Y.; Xu, J.; Tabernero, J.; Van Cutsem, E.; He, T.; Bhaumik, S.; Bhagia, P.; Janjigian, Y. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors
    Meeting Abstract

    Spira, A. I.; Papadopoulos, K. P.; Kim, D. W.; Parikh, A. R.; Barve, M. A.; Powderly, J. D. 2nd; Starodub, A.; Strickler, J. H.; Li, B. T.; Oberstein, P. E.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Genomic analysis of paired primary and metastatic pancreatic ductal adenocarcinoma tumors
    Meeting Abstract

    McIntyre, C. A.; Rudneva, V.; Richards, A. L.; Park, W.; Jarnagin, W. R.; Donoghue, M.; O'Reilly, E. M.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST)
    Meeting Abstract

    Trent, J. C.; Wagner, A. J.; Attia, S.; Agulnik, M.; Wilky, B. A.; Tap, W. D.; von Mehren, M.; Davis, E. J.; Zou, L.; Shah, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save